Jonathan Mitchell Dean's Insider Trades & SAST Disclosures
Jonathan Mitchell Dean's most recent trade in Praxis Precision Medicines Inc was a trade of 8,566 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 5, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Jonathan Mitchell Dean.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Praxis Precision Medicines... | Dean Jonathan Mitchell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 8,566 | 8,566 | - | - | Stock Option (Right to Buy) | |
| Theravance Biopharma Inc | Dean Jonathan Mitchell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2024 | 23,576 | 23,576 | - | - | Share Option (Right to Buy) | |
| Theravance Biopharma Inc | Dean Jonathan Mitchell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2024 | 10,537 | 80,555 (0%) | 0% | 0 | Ordinary Shares | |
| Precigen Inc | Dean Jonathan Mitchell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2024 | 101,626 | 101,626 | - | - | Option to Purchase Common Stock (Right to Buy) | |
| Precigen Inc | Dean Jonathan Mitchell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2024 | 87,412 | 87,412 | - | - | Restricted Stock Units | |
| Precigen Inc | Dean Jonathan Mitchell | Director | Grant, award, or other acquisition of securities at price $ 1.43 per share. | 14 Mar 2024 | 39,510 | 503,183 (0%) | 0% | 1.4 | 56,499 | Common Stock |
| Precigen Inc | Dean Jonathan Mitchell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2024 | 106,837 | 0 | - | - | Restricted Stock Units | |
| Precigen Inc | Dean Jonathan Mitchell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2024 | 106,837 | 463,673 (0%) | 0% | - | Common Stock | |
| Immunogen, Inc. | Jonathan Mitchell Dean | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.70 per share. | 22 Sep 2023 | 10,000 | 103,000 (0%) | 0% | 14.7 | 147,000 | Common Stock |
| Immunogen, Inc. | Dean Jonathan Mitchell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 19,597 | 19,597 | - | - | Stock Option (right to buy) | |
| Immunogen, Inc. | Dean Jonathan Mitchell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 13,090 | 13,090 | - | - | Restricted Stock Unit | |
| Praxis Precision Medicines... | Dean Jonathan Mitchell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2023 | 28,981 | 28,981 | - | - | Stock Option (Right to Buy) | |
| Kinnate Biopharma Inc | Dean Jonathan Mitchell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2023 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Theravance Biopharma Inc | Dean Jonathan Mitchell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2023 | 22,044 | 22,044 | - | - | Share Option (Right to Buy) | |
| Theravance Biopharma Inc | Dean Jonathan Mitchell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2023 | 9,132 | 70,018 (0%) | 0% | 0 | Ordinary Shares | |
| Praxis Precision Medicines... | Dean Jonathan Mitchell | Director | Purchase of securities on an exchange or from another person at price $ 0.84 per share. | 24 Mar 2023 | 50,000 | 75,000 | - | 0.8 | 41,815 | Common Stock |
| Precigen Inc | Dean Jonathan Mitchell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2023 | 125,489 | 125,489 | - | - | Option to Purchase Common Stock (Right to Buy) | |
| Precigen Inc | Dean Jonathan Mitchell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2023 | 106,837 | 106,837 | - | - | Restricted Stock Units | |
| Precigen Inc | Dean Jonathan Mitchell | Director | Grant, award, or other acquisition of securities at price $ 1.17 per share. | 09 Mar 2023 | 48,290 | 331,836 (0%) | 0% | 1.2 | 56,499 | Common Stock |
| Precigen Inc | Dean Jonathan Mitchell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2023 | 61,576 | 0 | - | - | Restricted Stock Units | |
| Precigen Inc | Dean Jonathan Mitchell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2023 | 61,576 | 283,546 (0%) | 0% | - | Common Stock | |
| Immunogen, Inc. | Dean Jonathan Mitchell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Dec 2022 | 3,024 | 142,667 | - | - | Deferred Share Unit | |
| Immunogen, Inc. | Dean Jonathan Mitchell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2022 | 3,138 | 139,643 | - | - | Deferred Share Unit | |
| Immunogen, Inc. | Dean Jonathan Mitchell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2022 | 3,333 | 136,505 | - | - | Deferred Share Unit | |
| Immunogen, Inc. | Dean Jonathan Mitchell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 44,000 | 44,000 | - | - | Stock Option (right to buy) | |
| Immunogen, Inc. | Dean Jonathan Mitchell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 15,000 | 133,172 | - | - | Deferred Share Unit | |
| Kinnate Biopharma Inc | Dean Jonathan Mitchell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2022 | 20,250 | 20,250 | - | - | Stock Option (right to buy) | |
| Praxis Precision Medicines... | Dean Jonathan Mitchell | Director | Purchase of securities on an exchange or from another person at price $ 1.81 per share. | 08 Jun 2022 | 25,000 | 25,000 | - | 1.8 | 45,188 | Common Stock |
| Praxis Precision Medicines... | Dean Jonathan Mitchell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2022 | 22,753 | 22,753 | - | - | Stock Option (Right to Buy) | |
| Theravance Biopharma Inc | Dean Jonathan Mitchell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Apr 2022 | 28,000 | 28,000 | - | - | Share Option (Right to Buy) | |
| Theravance Biopharma Inc | Dean Jonathan Mitchell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Apr 2022 | 9,852 | 60,886 (0%) | 0% | 0 | Ordinary Shares | |
| Immunogen, Inc. | Dean Jonathan Mitchell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2022 | 3,151 | 118,172 | - | - | Deferred Share Unit | |
| Precigen Inc | Dean Jonathan Mitchell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Mar 2022 | 16,212 | 221,970 (0%) | 0% | - | Common Stock | |
| Precigen Inc | Dean Jonathan Mitchell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Mar 2022 | 16,212 | 0 | - | - | Restricted Stock Units | |
| Precigen Inc | Dean Jonathan Mitchell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2022 | 83,189 | 83,189 | - | - | Option to Purchase Common Stock (Right to Buy) | |
| Precigen Inc | Dean Jonathan Mitchell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2022 | 61,576 | 61,576 | - | - | Restricted Stock Units | |
| Precigen Inc | Dean Jonathan Mitchell | Director | Grant, award, or other acquisition of securities at price $ 2.03 per share. | 22 Feb 2022 | 27,832 | 205,758 (0%) | 0% | 2.0 | 56,499 | Common Stock |
| Immunogen, Inc. | Dean Jonathan Mitchell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2021 | 2,380 | 113,202 | - | - | Deferred Share Unit | |
| Immunogen, Inc. | Dean Jonathan Mitchell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2021 | 50,000 | 0 | - | - | Stock Option (right to buy) | |
| Immunogen, Inc. | Dean Jonathan Mitchell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.56 per share. | 03 Sep 2021 | 50,000 | 93,000 (0%) | 0% | 4.6 | 228,000 | Common Stock |
| Immunogen, Inc. | Dean Jonathan Mitchell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2021 | 18,000 | 0 | - | - | Stock Option (right to buy) | |
| Immunogen, Inc. | Dean Jonathan Mitchell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.10 per share. | 03 Sep 2021 | 18,000 | 43,000 (0%) | 0% | 2.1 | 37,800 | Common Stock |
| Immunogen, Inc. | Dean Jonathan Mitchell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.64 per share. | 03 Sep 2021 | 10,000 | 25,000 (0%) | 0% | 4.6 | 46,400 | Common Stock |
| Immunogen, Inc. | Dean Jonathan Mitchell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2021 | 10,000 | 0 | - | - | Stock Option (right to buy) | |
| Immunogen, Inc. | Dean Jonathan Mitchell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2021 | 5,000 | 0 | - | - | Stock Option (right to buy) | |
| Immunogen, Inc. | Dean Jonathan Mitchell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.84 per share. | 03 Sep 2021 | 5,000 | 15,000 (0%) | 0% | 1.8 | 9,200 | Common Stock |
| Immunogen, Inc. | Dean Jonathan Mitchell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2021 | 2,048 | 110,822 | - | - | Deferred Share Unit | |
| Immunogen, Inc. | Dean Jonathan Mitchell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2021 | 44,000 | 44,000 | - | - | Stock Option (right to buy) | |
| Immunogen, Inc. | Dean Jonathan Mitchell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2021 | 15,000 | 108,774 | - | - | Deferred Share Unit | |
| Kinnate Biopharma Inc | Dean Jonathan Mitchell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2021 | 20,250 | 20,250 | - | - | Stock Option (right to buy) | |
| Praxis Precision Medicines... | Dean Jonathan Mitchell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 22,343 | 22,343 | - | - | Stock Option (Right to Buy) | |
| Theravance Biopharma Inc | Dean Jonathan Mitchell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Apr 2021 | 9,828 | 51,034 (0%) | 0% | 0 | Ordinary Shares | |
| Theravance Biopharma Inc | Dean Jonathan Mitchell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Apr 2021 | 6,000 | 6,000 | - | - | Share Option (Right to Buy) | |
| Immunogen, Inc. | Dean Jonathan Mitchell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2021 | 1,666 | 93,774 | - | - | Deferred Share Unit | |
| Precigen Inc | Dean Jonathan Mitchell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2021 | 22,107 | 22,107 | - | - | Option to Purchase Common Stock (Right to Buy) | |
| Precigen Inc | Dean Jonathan Mitchell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2021 | 16,212 | 16,212 | - | - | Restricted Stock Units | |
| Precigen Inc | Dean Jonathan Mitchell | Director | Grant, award, or other acquisition of securities at price $ 7.71 per share. | 25 Mar 2021 | 7,328 | 177,926 (0%) | 0% | 7.7 | 56,499 | Common Stock |
| Precigen Inc | Dean Jonathan Mitchell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Mar 2021 | 62,189 | 0 | - | - | Restricted Stock Units | |
| Precigen Inc | Dean Jonathan Mitchell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Mar 2021 | 62,189 | 170,598 (0%) | 0% | - | Common Stock | |
| Precigen Inc | Dean Jonathan Mitchell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.69 per share. | 03 Mar 2021 | 2,968 | 108,409 (0%) | 0% | 5.7 | 16,888 | Common Stock |
| Precigen Inc | Dean Jonathan Mitchell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2021 | 2,968 | 0 | - | - | Option to Purchase Common Stock (Right to Buy) | |
| Immunogen, Inc. | Dean Jonathan Mitchell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2020 | 3,750 | 90,015 | - | - | Deferred Share Unit | |
| Immunogen, Inc. | Dean Jonathan Mitchell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2020 | 2,934 | 86,265 | - | - | Deferred Share Unit | |
| Precigen Inc | Dean Jonathan Mitchell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jun 2020 | 2,968 | 0 | - | - | Option to Purchase Common Stock (Right to Buy) | |
| Precigen Inc | Dean Jonathan Mitchell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.17 per share. | 19 Jun 2020 | 2,968 | 105,441 (0%) | 0% | 3.2 | 9,409 | Common Stock |
| Immunogen, Inc. | Dean Jonathan Mitchell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2020 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Immunogen, Inc. | Dean Jonathan Mitchell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2020 | 17,000 | 83,331 | - | - | Deferred Share Unit | |
| Theravance Biopharma Inc | Dean Jonathan Mitchell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Apr 2020 | 6,635 | 41,206 (0%) | 0% | 0 | Ordinary Shares | |
| Theravance Biopharma Inc | Dean Jonathan Mitchell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Apr 2020 | 6,000 | 6,000 | - | - | Share Option (Right to Buy) | |
| Immunogen, Inc. | Dean Jonathan Mitchell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2020 | 3,958 | 66,331 | - | - | Deferred Share Unit |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges